A Review of Psychophysiological Stressors on Pharmacokinetics

Defence Research and Development Canada-Toronto, 1133 Sheppard Avenue West, P.O. Box 2000, Toronto, Ontario, Canada M3M 3B9.
The Journal of Clinical Pharmacology (Impact Factor: 2.48). 11/2011; 51(11):1499-518. DOI: 10.1177/0091270010393344
Source: PubMed

ABSTRACT We conducted a comprehensive literature review on the effects of psychophysiological stressors on the pharmacokinetics of drugs commonly used by the Canadian Forces. These stressors may change the physiological status of an individual and subsequently may alter the drug's pharmacokinetics. The effects of isolated physical activities on pharmacokinetics have been well documented. However, the findings are inconsistent due to variations in the intensity and duration of the activity, and the routes and timing of drug administration. The effects of other environmental stressors, such as temperature extremes, hypobaric, hyperbaric, hyperoxic conditions, and the effects of multiple stressors are less well known. There are limited studies describing the effects of psychological stressors on drug pharmacokinetics. Further studies are necessary to understand the clinical implications of pharmacokinetic changes. We also discussed the advantage of using a physiologically based pharmacokinetic model to predict the effects of a single or multiple stressors.

Download full-text


Available from: Henry T Peng, Jan 01, 2015
24 Reads
  • Source
    • "Besides, many non-pharmacological factors such as age, gender, psychological/social elements also impact the overall therapeutic outcome20. It is a common phenomenon that depressive disorder perturbs the drug efficacy in clinical practice2122. However, it is unclear whether depression perturbs the drug metabolic process of the hypoglycemic agents in diabetic medication or not. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Many diabetic patients complicated with wild to severe depression. It is unclear in diabetic medication whether depression perturbs the drug metabolic process of the hypoglycemic agents or not. The present study was designed to investigate the impact of chronic unpredicted mild stress (CUMS) -induced depression on mitiglinide (MGN) pharmacokinetics in rats. Adult female Sprague-Dawley rats in CUMS group were subjected to different types of stressors and the stress procedures lasted for 8 weeks. Control group without receiving stress had free access to food and water. Open-field test and 5-HT levels were assayed to evaluate the depression. After CUMS all rats were given 2.5 mg/kg of mitiglinide per os. The blood samples were collected at different time and mitiglinide plasma concentration was measured by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Non-compartmental statistical moment analysis was processed with DAS software. In CMUS-induced depression group, peak concentration (Cmax), peak time (Tmax), area under curve (AUC0 → ∞), mean residence time (MRT0 → ∞), and half-life (T1/2z) were reduced while total plasma clearance (CLz/F) was increased compared to control group. These preliminary results indicated that CUMS-induced depression alter the drug metabolic process of mitiglinide in rats. This finding will be significant in clinic.
    Scientific Reports 01/2014; 4:3794. DOI:10.1038/srep03794 · 5.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug metabolism is affected by many social-psychological factors including mood disorder. Organ transplantation recipients usually suffer from depression. The study aims to explore whether depression disorder alters immunosuppresant Tacrolimus (TAC) pharmacokinetic process in depression model rats. Eighteen female Sprague-Dawley (SD) rats were randomized into model group and control group. Depression model rats were built with Chronic Unpredicted Mild Stresses (CUMS) for 8 weeks. After 8 weeks model establishment, all rats in both groups were given TAC (1.5 mg kg(-1)) i.g. Blood samples were collected at various time points. TAC concentration was assayed by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). TAO pharmacokinetic parameters were processed with DAS software. Compared to those in control group, there was significant decrease in C-max and AUC in depression model group (p<0.05), from 0.87+/-0.06 to 0.79+/-0.05 mu g mL(-1)(C-max) and from 2.35+/-0.23 to 2.14+/-0.08 mu g mL(-1).h (AUC), respectively. The results indicated that depression disorder alter TAC pharmacokinetic process which might be induced by enhancing the drug metabolism.
    International Journal of Pharmacology 04/2013; 9(4):265-270. DOI:10.3923/ijp.2013.265.270 · 0.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The available evidence suggests that psychophysiological stress regulates a substantial number of factors, which in turn, can alter the pharmacokinetic parameters of a drug. Areas covered: Due to the multi-factorial involvement of stress in the regulation of a drug's pharmacokinetic profile, this review has been limited to and focuses only on the impact of stress on drug metabolism. Specifically, the review presents studies which have indicated that psychophysiological stress can significantly modify the function of the major hepatic drug-metabolizing enzymes belonging to cytochrome P450s (CYP) family in a stress-specific and species-specific manner. Furthermore, the article discusses how stress related changes in CYP regulation appear to be mediated by glucocorticoids and epinephrine/norepinephrine. This can lead to an increased rate of metabolism of the majority of prescribed drugs and chemical pre-carcinogens. Expert opinion: Apparently, psychophysiological stress has a significant impact on some of the major drug-metabolizing enzyme systems. Therefore, stress should be considered as an important factor affecting drug metabolism and pharmacokinetics, with the potential to significantly alter the outcome of drug therapy and toxicity. Despite the fact that the majority of data come from experimental studies, it is conceivable that the elimination of stress is an essential condition in order to ensure the optimal outcome of pharmacotherapy.
    Expert Opinion on Drug Metabolism &amp Toxicology 07/2013; 9(10). DOI:10.1517/17425255.2013.816283 · 2.83 Impact Factor
Show more